Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2053

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2053
---
 product candidates.

    ●
    The
    intellectual property that we have in-licensed has been discovered through government funded programs and thus may be subject to
    federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies.
    Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.

    ●
    We
    have entered into and may enter into license, sublicense or other collaboration agreements in the future that may impose certain
    obligations on us. If we fail to comply with our obligations under such agreements with third parties, we could lose license or sublicense
    rights that may be important to our future business.

    ●
    Obtaining
    and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
    imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

7

    ●
    Our
    internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches,
    which could result in a material disruption of our product development programs.

    ●
    We
    may encounter difficulties in managing our growth, which could adversely affect our operations.

    ●
    If
    we lose key management or scientific personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop
    current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market
    share and could make us less competitive.

    ●
    We
    identified material weaknesses in the Company’s internal control over financial reporting. If our remediation of these material
    weaknesses is not effective, or if we experience additional material weaknesses or otherwise fail to maintain an effective system of
    internal controls in the future, we may not be able to accurately report our financial condition or results of operations.

    ●
    Even
    if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory
    review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory
    requirements or experience unanticipated problems with our product candidates.

    ●
    Ongoing
    healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.

    ●
    The
    price of our common stock